Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease

Clinical and Experimental Nephrology

Volumn 16, Issue 1, 2012, Pages 102-108

  Tsujimura, Shizuyo ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Disease activity; Lymphocytes; Multidrug resistance 1 gene; P glycoprotein; Systemic autoimmune disease

Indexed keywords

ANTHRACYCLINE; ANTIMALARIAL AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DEXAMETHASONE; DEXVERAPAMIL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; GLYCOPROTEIN P SYNTHESIS INHIBITOR; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; POISON; PREDNISOLONE; PROTEIN SYNTHESIS INHIBITOR; QUINIDINE; SALAZOSULFAPYRIDINE; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINCA ALKALOID; XENOBIOTIC AGENT;

AUTOIMMUNE DISEASE; CELL STRESS; CYTOPLASM; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TARGETING; DRUG TRANSPORT; GENOTOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MULTIDRUG RESISTANCE; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; P-GLYCOPROTEIN;

EID: 84858283166     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0520-3     Document Type: Review

References (21)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-16. (Pubitemid 32224400)
2. Jorgensen C, Maillefert JF. Multidrug resistance genes in rheumatology. Is their role immunological or pharmacological? Joint Bone Spine. 2000;67:8-10. (Pubitemid 30216933)
3. Mader R, Schonfeld S. Malabsorption in systemic lupus erythematosus. Harefuah. 1990;118:572-3.
4. Takeshita A, Taguchi M, Koibuchi N, Ozawa Y. Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem. 2002;277:32453-8. (Pubitemid 34984746)
5. Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci. 2003;94:9-14. (Pubitemid 36575851)
6. Leonard GD, Polgar O, Bates SE. ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs. 2002;3: 1652-9. (Pubitemid 36266743)
7. McKeegan KS, Borges-Walmsley MI, Walmsley AR. The structure and function of drug pumps: an update. Trends Microbiol. 2003;11:21-9. (Pubitemid 36084352)
8. Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracyclines antibiotics. Cancer Treat Rep. 1983;67:889-94. (Pubitemid 14231380)
9. Ueda K, Cardaralli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human "MDR-1" gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987;84:3004-8. (Pubitemid 17064766)
10. Salmon SE, Dalton WS. Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. J Rheumatol. 1996;S44:97-101. (Pubitemid 26094654)
11. List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, et al. Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood. 2002;100:1910-2. (Pubitemid 34925173)
12. Bourgeois S, Gruol DJ, Newby BRF, Rajah FM. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol. 1993;7:840-51. (Pubitemid 23220634)
13. van der Heijden JW, Oerlemans R, Tak PP, Assaraf YG, Kraan MC, Scheffer GL, et al. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum. 2009;60:669-77.
14. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, et al. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells. 2004;9:1265-73. (Pubitemid 39618539)
15. Tsujimura S, Saito K, Kohno K, Tanaka Y. Fragmented hyaluronan induces transcriptional up-regulation of the multidrug resistance-1 gene in CD4+ T cells. J Biol Chem. 2006;281:38089-97. (Pubitemid 46042112)
16. Tsujimura S, Saito K, Nakayamada S, Tanaka Y. Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Mod Rheumatol. 2010;20:139-46.
17. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52: 1676-83. (Pubitemid 40852875)
18. Tsujimura S, Saito K, Tokunaga M, Nakatsuka K, Nakayamada S, Nakano K, et al. Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Mod Rheumatol. 2005;15:28-32. (Pubitemid 40298419)
19. Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M, et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem. 1988;273:5997-6000.
20. Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, et al. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol. 1999;457:47-56. (Pubitemid 129735297)
21. Fisher GA, Lum BL, Hausdorff J, Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer. 1996;32A:1082-8.